p53-Y220C-BET Bifunctional

About Photys Therapeutics

Photys Therapeutics is a private, preclinical-stage biotech founded in 2021, based on pioneering bifunctional chemistry from the Broad Institute. The company has developed a versatile platform of proximity-inducing chimeric molecules (PROTACs, tPRIME, PHICS) designed to degrade, transcriptionally regulate, or phosphorylate target proteins with high precision. Backed by a $75M Series A and strategic collaborations with Novo Nordisk and Polymed, Photys is advancing a pipeline aimed at historically challenging targets in oncology, immunology, and cardiometabolic disorders.

Therapeutic Areas